Table 4 Characteristics of DANBLOCK, REDUCE-SWEDEHEART, and BETAMI
| Â | DANBLOCK | REDUCE-SWEDEHEART | BETAMI |
|---|---|---|---|
Inclusion criteria | |||
 Age | ≥ 18 years | ≥ 18 years | ≥ 18 years |
 MI definition | The universal definition of MI | The universal definition of MI (type 1) | The universal definition of MI (type 1) |
 Randomized prior to | Day 14 after MI | Day 7 after MI | Not specified |
 Revascularization | No criteria for revascularization | Obstructive coronary artery disease documented by coronary angiography | PCI or thrombolysis during hospitalization |
 LVEF cutoff value | > 40% | ≥ 50% | ≥ 40% |
Exclusion criteria | Any medical condition where beta-blocker therapy is indicated or contraindicated according to the treating physician | Any medical condition where beta-blocker therapy is indicated or contraindicated according to the treating physician | Any medical condition where beta-blocker therapy is indicated or contraindicated according to the treating physician |
Primary endpoints | A composite of all-cause mortality and hospitalization for recurrent non-fatal MI, unstable angina pectoris, stroke, and acute decompensated heart failure | Time to the composite of death of any cause or MI | Time to the composite of all cause mortality or non-fatal MI |
Expected number of randomized patients | 3570 | 7000 | 10,000 |
Expected number of events | 900 | 944 | 794 |
Expected number of events to contribute to a pooled meta-analysis | 632 | 944 | 794 |
Individual study power if true HR was 1.2 | 0.619 | 0.797 | 0.732 |